Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

714 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL Jr, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Sarraju A, et al. Among authors: neal b. J Am Coll Cardiol. 2022 Nov 1;80(18):1721-1731. doi: 10.1016/j.jacc.2022.08.772. J Am Coll Cardiol. 2022. PMID: 36302584 Free article. Clinical Trial.
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial.
Koshino A, Neuen BL, Oshima M, Toyama T, Hara A, Arnott C, Neal B, Jardine M, Badve SV, Mahaffey KW, Pollock C, Hansen MK, Wada T, Heerspink HJL. Koshino A, et al. Among authors: neal b. Kidney Int Rep. 2023 Dec 1;9(2):347-355. doi: 10.1016/j.ekir.2023.11.024. eCollection 2024 Feb. Kidney Int Rep. 2023. PMID: 38344715 Free PMC article.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Charytan DM, et al. Among authors: neal b. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270. BMJ Open Diabetes Res Care. 2023. PMID: 37311602 Free PMC article. Clinical Trial.
Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Sen T, Ju W, Nair V, Ladd P, Menon R, Otto EA, Pyle L, Vigers T, Nelson RG, Arnott C, Neal B, Hansen MK, Kretzler M, Bjornstad P, Heerspink HJL. Sen T, et al. Among authors: neal b. Kidney Int. 2023 Oct;104(4):828-839. doi: 10.1016/j.kint.2023.07.007. Epub 2023 Aug 4. Kidney Int. 2023. PMID: 37543256 Free article.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
714 results